Hui Feng, MD, PhD

Assistant Professor, Pharmacology & Experimental Therapeutics

Hui Feng
(617) 638-4171
72 E. Concord St Silvio Conte (K)

Biography

Cancer Research: Dr. Feng is Director of the Laboratory of Zebrafish Genetics and Cancer Therapeutics. Dr. Feng’s research interests focus on identifying novel genes and pathways that are essential for MYC-related tumor transformation and progression, particularly for T-Lymphoblastic Lymphoma/Leukemia, Neuroblastoma and Breast Cancer. The research strategy of Dr. Feng’s research is to combine the analysis of human cancer cells with the genetic and imaging capacities of the zebrafish system.

Current research areas in Dr. Feng’s laboratory include:
1) To determine the molecular mechanisms underlying tumor cell intravasation and tumor progression.
2) To identify novel genes and pathways that, when mutated, delay the initiation and progression of MYC-related cancers.
3) To test the identified genes’ therapeutic potential in treating MYC-related cancers and to characterize their molecular relevance to MYC.

The long-term goal of Dr. Feng’s research is to discover novel molecular therapies to target critical components of MYC-driven oncogenic pathways, thus providing treatment alternatives that are more specific and less toxic.

Education

  • Beijing Medical University, MD
  • University of Georgia, PhD
  • Peking Union Medical College, MS

Publications

  • Published on 10/6/2016

    Lian H, Li D, Zhou Y, Landesman-Bollag E, Zhang G, Anderson NM, Tang KC, Roderick JE, Kelliher MA, Seldin DC, Fu H, Feng H. CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells. Haematologica. 2017 Jan; 102(1):e17-e21. PMID: 27758824.

    Read at: PubMed
  • Published on 2/1/2016

    Anderson NM, Li D, Peng HL, Laroche FJF, Mansour MR, Gjini E, Aioub M, Helman DJ, Roderick JE, Cheng T, Harrold I, Samaha Y, Meng L, Amsterdam A, Neuberg DS, Denton TT, Sanda T, Kelliher MA, Singh A, Look AT, and Feng H. The TCA Cycle Transferase DLST is Important for MYC-mediated Leukemogenesis. Leukemia. 2016.

  • Published on 1/1/2016

    Harrison NR, Laroche FJ, Gutierrez A, Feng H. Zebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights. Adv Exp Med Biol. 2016; 916:335-69. PMID: 27165361.

    Read at: PubMed
  • Published on 1/1/2016

    Harrold I, Carbonneau S, Moore BM, Nguyen G, Anderson NM, Saini AS, Kanki JP, Jette CA, Feng H. Efficient transgenesis mediated by pigmentation rescue in zebrafish. Biotechniques. 2016 Jan; 60(1):13-20. PMID: 26757807.

    Read at: PubMed
  • Published on 6/10/2015

    Srinivasan S, Chitalia V, Meyer RD, Hartsough E, Mehta M, Harrold I, Anderson N, Feng H, Smith LE, Jiang Y, Costello CE, Rahimi N. Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis. Angiogenesis. 2015 Oct; 18(4):449-62. PMID: 26059764.

    Read at: PubMed
  • Published on 5/4/2015

    Huiting L, Laroche, FJF, Feng H. The Zebrafish as a Tool to Cancer Drug Discovery. Austin Journal of Pharmacology and Therapeutics. Austin Journal of Pharmacology and Therapeutics. Secaucus. 2015; 2(3):1069.

  • Published on 5/4/2015

    Huiting LN, Laroche F, Feng H. The Zebrafish as a Tool to Cancer Drug Discovery. Austin J Pharmacol Ther. 2015; 3(2):1069. PMID: 26835511.

    Read at: PubMed
  • Published on 3/17/2015

    Shivanna S, Harrold I, Shashar M, Meyer R, Kiang C, Francis J, Zhao Q, Feng H, Edelman ER, Rahimi N, Chitalia VC. The c-Cbl ubiquitin ligase regulates nuclear ß-catenin and angiogenesis by its tyrosine phosphorylation mediated through the Wnt signaling pathway. J Biol Chem. 2015 May 15; 290(20):12537-46. PMID: 25784557.

    Read at: PubMed
  • Published on 4/2/2014

    Gutierrez A, Feng H, Stevenson K, Neuberg DS, Calzada O, Zhou Y, Langenau DM, Look AT. Loss of function tp53 mutations do not accelerate the onset of myc-induced T-cell acute lymphoblastic leukaemia in the zebrafish. Br J Haematol. 2014 Jul; 166(1):84-90. PMID: 24690081.

    Read at: PubMed
  • Published on 12/17/2013

    Anderson NM, Harrold I, Mansour MR, Sanda T, McKeown M, Nagykary N, Bradner JE, Lan Zhang G, Look AT, Feng H. BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines. Leukemia. 2014 May; 28(5):1145-8. PMID: 24342948.

    Read at: PubMed

View 12 more publications: View full profile at BUMC

View all profiles